Retro Biosciences Achieves $1.8 Billion Valuation in Latest Fundraising Round
Retro Biosciences, a startup focused on longevity and supported by OpenAI's Sam Altman, has successfully raised additional funds, reaching a valuation of $1.8 billion.
Editorial Staff
1 min read
Updated 18 days ago
Retro Biosciences has announced that it has raised more funds, leading to a valuation of $1.8 billion. This marks a significant milestone for the longevity-focused startup.
The company is notably backed by Sam Altman, the CEO of OpenAI, which adds to its credibility in the tech and health sectors.
This funding round reflects growing interest and investment in longevity research and technologies, although the specific details of the fundraising have not been disclosed.